SANOMACHI TOMOMI

サノマチトモミ | SANOMACHI TOMOMI

Affiliation and department：
Research theme for competitive and other funds (3)：

2024 - 2025 医療従事者間のオンラインコンサルテーションシステムを基盤にした地域のがん診療の均霑化に向けた医療提供体制整備に関する研究
2020 - 2022 Basic research aimed at developing new drug therapies for malignant meningioma
2018 - 2021 Basic research aimed at establishing effective chemotherapy for malignant meningioma

Papers (32)：

Tomomi SANOMACHI, Tatsuya YOSHIDA, Ryoko INABA HIGASHIYAMA, Yaya SATOZONO, Shiho MATSUNAGA, Yukihide KANEMITSU, Yuichiro OHE. Ileal perforation at the site of peritoneal metastasis with intestinal infiltration by dual EGFR-VEGF pathway inhibition in an EGFR-mutant non-small cell lung cancer patient. International Cancer Conference Journal. 2024
Tomomi Sanomachi, Hiroto Ishiki. Classifying and grading liposarcoma by CT. The Lancet. Oncology. 2024. 25. 2. e53
Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Kan Yonemori. COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation. International cancer conference journal. 2023. 12. 3. 216-219
Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Kan Yonemori. Correction to: COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation. International cancer conference journal. 2023. 12. 3. 220-220
Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai, Asuka Kawachi, Shu Yazaki, Momoko Tokura, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, et al. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. Frontiers in oncology. 2023. 13. 1157789-1157789

ｍore...

MISC (38)：

T. Sanomachi, T. Shimoi, Y. Kojima, A. Kawachi, H. Sumiyoshi Okuma, M. Hoshino, M. Ito, A. Saito, S. Kita, A. Maejima, et al. O9-5 Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy. Annals of Oncology. 2024. 35. S1319-S1319
T. Sanomachi, A. Ohba, N. Ogura, H. Hara, S. Yagi, M.O. Okada, Y. Maruki, Y. Nagashio, S. Kondo, H. Susumu, et al. 341P Clinical experience with S-1 or FOLFOX as third-line treatment in patients with metastatic pancreatic cancer who received first-line gemcitabine + nab-paclitaxel and second-line nanoliposomal-irinotecan + 5-FU/leucovorin. Annals of Oncology. 2024. 35. S142-S142
佐野町友美, 牛尼美年子, 牛尼美年子, 後藤政広, 張萌琳, 田辺記子, 渡辺智子, 松川愛未, 小田智世, 小高陽子, et al. Li-Fraumeni症候群におけるTP53遺伝子病的バリアントのサブタイプ別の罹患がんの関連解析. 日本遺伝性腫瘍学会学術集会プログラム・抄録集. 2024. 30th
佐野町友美, 森實千種. Supportive care in hepatobiliary and pancreatic cancers. 臨床外科. 2024. 79. 7
T. Sanomachi, T. Shimoi, A. Kawachi, H.S. Okuma, M. Hoshino, M. Ito, A. Saito, S. Kita, A. Maejima, Y. Kojima, et al. 1722P Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases. Annals of Oncology. 2023. 34. S938-S938

ｍore...

Books (2)：

Lectures and oral presentations (11)：

Comparison of efficacy of platinum doublet chemotherapy with and without ICIs in treatment naïve advanced HER2 mutant NSCLC patients
(2024)
ASCO/JSCOフェローシップ2024を通して学んだ日米の薬剤開発の現状と課題
(第62回日本癌治療学会学術集会 2024)
Li-Fraumeni症候群におけるTP53遺伝子病的バリアントのサブタイプ別の罹患がんの関連解析
(第30回日本遺伝性腫瘍学会学術集会 2024)
Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy
(2024)
Clinical characteristics of HER2-low stage I triple negative breast cancer
(2023)

ｍore...

Awards (4)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page